Collegium Pharmaceutical, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products. These products target market opportunities through formulation based product improvements protected by intellectual property. It builds a portfolio of pain products that incorporate its patent protected DETERx formulation platform that provides for extended release and tamper resistance. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Canton, MA.
